Apple appeals EU's €500M fine over App Store payment restraints
The European Commission issued the fine in April, saying that Apple failed to comply with the Digital Markets Act (DMA) rules to allow developers to accept payments for their apps outside Apple's ecosystem.
Apple revised its fee structure for app distribution in the EU in late June with a more complicated framework that includes an initial acquisition fee, a store services fee, along with a core technology commission to accommodate alternative payment methods. This move was likely to avoid further fines from the European Commission.
'We believe the European Commission's decision — and their unprecedented fine — go far beyond what the law requires. As our appeal will show, the EC is mandating how we run our store and forcing business terms which are confusing for developers and bad for users,' Apple told TechCrunch in a comment.
The story has been updated with Apple's comments
Inicia sesión para acceder a tu portafolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Which European economy stands to suffer the most from US tariffs?
Germany and Ireland are standing out as the two most exposed EU economies threatened by higher US tariffs, as Brussels works towards a trade deal with Washington, amid reports that pharmaceutical tariffs could be as high as 200%. When US President Donald Trump imposed a new 25% tariff on auto imports and car parts in April, Germany was identified as the EU country with the most to lose. Brussels-based think tank Bruegel's estimation at the time was that tariffs could cost 0.4% of the country's GDP in the long term. While awaiting a new EU-US trade deal, other details emerge that could put Ireland, Denmark, and Belgium, as well as other countries, in the crosshairs should Washington target the pharmaceutical sector next. The overall impact on the European economy will depend on the actual tariff rate the US settles on and the EU's response, but the blow will not be spread evenly. According to Bruegel, the EU economy is facing significant but manageable macroeconomic consequences. They estimated in a report in April that, regarding the possible scenarios, the damage could be approximately 0.3% of the EU's GDP, depending on the outcome of the negotiations. This compares to the 1.1% real GDP growth expected in the bloc in 2025, by the European Commission's Spring Forecast. Trade with the US is significant. In 2024, the United States was the largest partner for EU exports of goods, making up 20.6% of all EU goods exports outside the bloc. Pharmaceuticals account for 15% of the EU's goods exports to the US. They are followed by the auto sector. Until there is more clarification on potential US tariffs on the pharma sector's products, 'the auto sector seems to be the most vulnerable to US tariffs as there doesn't seem to be any major exemptions planned,' said Savary. The industry has been slapped with a 25% tariff in April. 'Tariffs alone could shave around 8% off total EU trade volumes over the next five years,' said Rory Fennessy, Senior Economist at Oxford Economics, in a recent report. Countries with the highest value in goods exports to the US, facing the biggest threat to their economies, include Germany, Ireland, Italy, France and the Netherlands. The German economy relies heavily on exports, boosted by the country's motor vehicle sector. Nearly one-quarter (22.7%) of the total German exports are heading to the US. 'Germany stands out as the major European economy likely to be hit hardest by US tariffs, and we expect GDP growth to slump in the second and third quarters," Andrew Hunter, Associate Director and Senior Economist at Moody's Ratings, said to Euronews Business. Hunter also added that smaller economies, including Austria and others in central and eastern Europe, 'which are heavily integrated into Germany's industrial supply chains, will also be hit hard'. According to Bruegel, after 2025, the long-term negative impact of the tariffs could be around 0.4% of the GDP in Germany, once 'the effect has fully built up and initial short-term effects dissipated,' said Niclas Frederic Poitiers, Research Fellow at Bruegel. 'For France, the average effect would be around 0.25% of GDP.' Related Lengthy trade wars could cut global investment by one-tenth, warn economists Trump the unifier? How Europe could benefit from Trump's policies Uncertainty could lead to lost investments and jobs across the entire 27-member bloc. Hunter said that, 'even for those countries where direct exposure to US exports is relatively limited, such as France or Spain, growth is still likely to be weighed down by global weakness and uncertainty. Regarding long-term impacts, Ireland stands out as one of the most affected countries, as more than half of its goods exports (53.7%) are directed towards the US market. A lot depends on whether the pharmaceutical sector will be hit with tariffs. If so, 'Ireland will be the EU economy most at risk from these tariffs,' said Mathieu Savary, chief strategist for our European Investment Strategy at BCA Research. The research-based pharmaceutical industry is a key asset of the European economy. It is one of Europe's top-performing high-technology sectors. It contributed €311 billion in gross value added (GVA) and 2.3 million jobs directly and indirectly to the European Union's economy in 2022, according to a recent study by PWC. And the US market is crucial to the European pharma sector. According to the European Federation of Pharmaceutical Industries and Associations, in 2021, North America accounted for 49.1% of world pharmaceutical sales compared with 23.4% for Europe. And more than one-third of EU pharma exports are going to the US. If the pharma sector is hit by a 25% tariff, as it is expected by Moody's in the coming months, 'most exposed would be a number of smaller European economies like Denmark, Belgium, Slovenia and Ireland, which are generally where we think the risks of recession in Europe are highest,' Hunter said. BCA Research's chief strategist added that in this case, 'Ireland is particularly exposed to this risk,' citing that exports to the US represent 18% of Ireland's GDP, and pharma exports represent nearly 55% of Irish exports. According to BCA, the impact 'could curtail 4% to 5% to growth over time'. Bruegel estimated that Ireland's cumulative real GDP loss could be 3% by 2028. The think tank also singled out the country as the most vulnerable regarding the impact of the US tariffs on employment. Regarding how vulnerable a country is to job losses in light of US tariffs, Bruegel said that Italy was the second most-exposed country, with a high exposure in transport equipment and a high level of exposed employment in fashion and car manufacturing. Italy would also have high exposure in pharmaceuticals. Trump said on Tuesday that pharmaceutical products imported to the US are facing a 200% tariff, without disclosing any further details. According to BCA's Savary, it is not likely, because 'that would massively increase the cost of healthcare for US consumers, which is already a major issue for voters.' He sees it as a 'strong message to foreign pharma companies to adjust their pricing down and invest into producing their drugs in the US.' Savary expects 'that FDIs into the US and drug prices reduction announcements will be the end result of these talks and threats'. 'The pressure is now on for drug companies to expand US production facilities so they are effectively on the doorstep of American customers,' said Dan Coatsworth, investment analyst at AJ Bell.
Business Insider
an hour ago
- Business Insider
Meta Thumbs its Nose to EU Charges After Refusing to Alter Ad Model
U.S. tech giant Meta Platforms (META) is standing up to Europe by refusing to make any changes to its advertising model, despite the threat of being slapped with daily fines by regulators. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Digital Compliance According to a Reuters report, Meta is believed to very 'unlikely' to offer up any alterations to its pay-or-consent model despite European pleas. Under the model, EU users of Facebook and Instagram have a choice between consenting to personal data combination for personalized advertising or paying a monthly subscription for an ad-free service. Earlier this year, the Commission found that this model is not compliant with its Digital Markets Act, as it did not give users the required specific choice to opt for a service that uses less of their personal data. As such, Meta, run by Mark Zuckerberg, was fined €200 million ($234 million) in April by the EU and warned that it would face daily fines if it did not make changes. Daily fines for not complying with the DMA can be as much as 5% of a company's average daily worldwide turnover. It is why legal and regulatory risk is such a key challenge for U.S. tech firms such as Meta. Closed for Business The Reuters report states that Meta will not propose additional changes unless circumstances change. This stance will likely result in new EU antitrust charges in the coming weeks. Meta has already blasted the EU and its Digital Markets Act by claiming that its crackdown means that Europe is 'closed for business.' It has also raised concerns about the EU's new AI Act, which has outlined a set of 'high-risk' uses, such as biometrics and facial recognition, or AI used in domains like education and employment. App developers will have to register their systems and meet risk and quality management obligations to gain EU access. Violations could draw fines of up to 35 million euros ($41 million), or 7% of a company's global revenue. Is META a Good Stock to Buy Now? On TipRanks, META has a Strong Buy consensus based on 42 Buy and 4 Hold ratings. Its highest price target is $918. META stock's consensus price target is $735.28 implying a 2.73% upside.
Yahoo
an hour ago
- Yahoo
Wall Street giant issues stark message on S&P 500
Wall Street giant issues stark message on S&P 500 originally appeared on TheStreet. The S&P 500 is back notching up all-time highs, capping off what's been a remarkable rebound. Things look very different for investors now, who are breathing easier after a rough start to the year. 💵💰💰💵 However, under the surface of this optimism, there is a hidden imbalance that continues to grow quietly. This risk is likely to turn today's party into tomorrow's headache if the momentum swings the other way. Over the past couple of years in particular, the 'Magnificent 7', which includes Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta, and Tesla, have turned the S&P 500 into their personal growth machine. Back in mid-2023, these mega-caps accounted for a whopping one-third of the index's market value. By early 2024, that number grew even more, creeping up to 35%. That figure is now pushing toward 40%, the highest concentration level in more than 50 years. It's not hard to gauge, though, if we look at the scoreboard. Nvidia is up an eye-popping 936% over the past three years, Meta's up 326%, Amazon popped 93%, and Apple notched a 44% gain, beating the broader index by a country those blockbuster runs supercharged passive portfolios but also rewired the S&P 500. Critics say index investors aren't getting true diversification anymore. Instead, they're loaded by a select few pricey tech stocks that could switch gears in a regulatory crackdown or if earnings miss following a major stumble. The risks are too real to ignore for savvy investors. Nvidia's sky-high valuations continue raising eyebrows (having flirted with $4 trillion market cap recently). Apple faces antitrust probes in Europe. Google's ad business is under fresh scrutiny. Also, EV giant Tesla's once-torrid growth has cooled off. More Tech Stock News: Tesla's next bet could flip the robotaxi race Cathie Wood shells out $13.9 million for one high-stakes biotech stock Apple's quiet shake-up could redefine its future It's giving investors flashbacks to the 'Nifty Fifty' collapse of the 1970s, when overconfidence in a few blue chips ended in major pain. Wall Street giant Apollo has just put out a fresh warning on those holding the S&P 500. According to Apollo Chief Economist Torsten Sløk, investors looking for the traditional 'broad diversification' from the S&P 500 are essentially betting on the Mag 7, which continues powering ahead. Collectively, these mega-cap titans now account for roughly 40% of the S&P 500's total market value. That's a paradigm shift from what the benchmark index intended to do, which was to spread your risk across 500 companies, sectors, and problem is, when you have just seven names propping up almost half the index, a bad day for Big Tech can result in a massive setback for everyone. And tech stocks aren't living in a bubble. They're effectively linked to consumer spending, interest rates, and geopolitical tensions, and any surprise can rattle these giants quickly. Think of surprise antitrust crackdowns, AI hype cooling off, or disappointing earnings. Any of those worrying trends could send the Mag 7 sliding, dragging the entire index with them. It's no wonder that many strategists are concerned about how it's shaping their portfolios. For those worried about the major concentration risk, it will be more fruitful to dig deeper and hunt for smaller caps, dividend payers, or international stocks to look for real diversification. Apollo's takeaway is blunt. Passive index funds aren't the safety net they once were, and if you're in the S&P 500, you're basically betting all-in on Big Tech, regardless of whether you intend Street giant issues stark message on S&P 500 first appeared on TheStreet on Jul 11, 2025 This story was originally reported by TheStreet on Jul 11, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
